JMJD6 and ovarian carcinoma: As shown in Fig. 1a and Table 1, JMJD6 was highly and lowly expressed in 90 (61.64%) and 56 (38.36%) of the 146 ovarian cancer patients, respectively, according to the intensity of immunoreaction.